List view / Grid view
The catastrophic consequences of ever-increasing rates of death from infectious diseases demands new experimental strategies for drug target selection and drug design. Over the last decade, the pharmaceutical industry has been wounded by several issues including failure of drug-development programmes, burgeoning cost of drug development, increasing regulatory control, lack of…
Distinguishing whether bacteria are resistant to antibiotics or resilient to them is hugely important in determining the success of the treatment...
An immunoassay developed to analyse small molecules has shown 50 times greater accuracy than current systems of analytical techniques...
Software that overlays tumour information from MRI scans onto ultrasound images could help to highlight areas of concern, and to detect and target cancer...
Frizzled receptors, from the GPCR family, could soon be a target to treat numerous diseases such as cancer, fibrosis and CVD...
Researchers have developed nanoscale 'tweezers' used to investigate single living cells, which could help to identify why healthy cells become diseased...
Researchers have genetically engineered immune cells to recognise and fight Hodgkin and non-Hodgkin lymphoma cells...
Nanoscientists have identified genes that link to dementia, in the hope that future therapies could target these genes for positive results in patients...
ZFP64, an inconspicuous MLL fusion protein was found to be neccessary for the production of MLL proteins, and could be targeted to inprove outcomes of MLL...
Restoring brain cell receptors helps restore normal behaviour...
The Blue Brain 3D atlas could be the future of analysing all cells in the brain, with high quality, high resolution images that can navigate the brain...
Manchester University researchers have developed a high-throughput platform to analyse and study a family of enzymes that are linked to cancer...
Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.
With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.
A recently discovered enzyme could lead to the development of a treatment where cancer cells are starved of 'food' provided by this protein...
